ABSTRACT
The field of reproductive medicine has all but exploded in recent years, allowing more people access to novel treatments. New technologies have been introduced so rapidly that ethics and the law have been unable to respond appropriately. A particularly promising reproductive therapy, oocyte donation, and the wide variety of prenatal genetic tests already available, will theoretically present the legal world with a variety of new challenges. How should the law respond to potential wrongful birth and wrongful life suits resulting from failed genetic testing, if the child in question was conceived using a donor egg? Under what circumstances should the physician be held liable? Under what circumstances might the donor be culpable? This paper reviews scholarly opinions and existing case law in order to answer these questions.
Subject(s)
Liability, Legal , Oocyte Donation/legislation & jurisprudence , Wrongful Life , Genetic Diseases, Inborn , Genetic Testing/legislation & jurisprudence , Humans , Malpractice/legislation & jurisprudence , Parents , Physicians , Prenatal DiagnosisABSTRACT
The nonsteroidal anti-inflammatory drugs flurbiprofen and ibuprofen were modified in an attempt to alter the kinetics of inhibitor binding by COX-1. Contrary to prior predictions, a halogen substituent is not sufficient to confer slow tight-binding behavior. Conversion of the carboxylate moiety of flurbiprofen to an ester or amide abolishes slow tight-binding behavior, regardless of halogenation state.
